Cape Verde vs Libya: HIV/AIDS deaths averted by antiretroviral therapy
Cape Verde
176.27 deaths
in 2024
Libya
164.5 deaths
in 2024
Cape Verde rank
111th
Libya rank
114th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Cape Verde
- Libya
How they compare
Cape Verde currently reports 176.27 deaths against 164.5 deaths in Libya, a difference of 11.77 deaths.
That makes Cape Verde's figure about 1.1 times Libya's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Libya ahead.
Cape Verde ranks 111th and Libya ranks 114th of 157 countries.
Libya has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cape Verde | Libya | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 37.38 deaths | 58.07 deaths | 20.7 deaths | Libya |
| 2010s | 125.26 deaths | 191.14 deaths | 65.88 deaths | Libya |
| 2020s | 164.69 deaths | 175.32 deaths | 10.63 deaths | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Cape Verde or Libya?
- Cape Verde, at 176.27 deaths against 164.5 deaths in Libya as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Cape Verde and Libya?
- 11.77 deaths, with Cape Verde ahead.
- How many years of comparable data are there for Cape Verde and Libya?
- 35 years are reported by both, from 1990 to 2024.
- How do Cape Verde and Libya rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Cape Verde ranks 111th and Libya ranks 114th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.